Search Results

You are looking at 1 - 10 of 73 items for :

  • "Tyrosine kinase" x
Clear All
Zoe A. Efstathiadou Department of Endocrinology, “Hippokration” General Hospital of Thessaloniki, Thessaloniki, Greece

Search for other papers by Zoe A. Efstathiadou in
Google Scholar
PubMed
Close
,
Charalambos Tsentidis Department of Endocrinology, General Hospital of Nikaia “Agios Panteleimon”, Piraeus, Greece

Search for other papers by Charalambos Tsentidis in
Google Scholar
PubMed
Close
,
Alexandra Bargiota Department of Endocrinology, University of Thessaly, Larisa, Greece

Search for other papers by Alexandra Bargiota in
Google Scholar
PubMed
Close
,
Vasiliki Daraki Department of Endocrinology, University Hospital of Crete, Heraklion, Greece

Search for other papers by Vasiliki Daraki in
Google Scholar
PubMed
Close
,
Kalliopi Kotsa Department of Endocrinology, “Ahepa” Hospital, Aristotle University, Thessaloniki, Greece

Search for other papers by Kalliopi Kotsa in
Google Scholar
PubMed
Close
,
Georgia Ntali Department of Endocrinology, Diabetes and Metabolism, “Evangelismos” Hospital Athens, Athens, Greece

Search for other papers by Georgia Ntali in
Google Scholar
PubMed
Close
,
Labrini Papanastasiou Department of Endocrinology and Diabetes Center, Athens General Hospital “G. Gennimatas”, Athens, Greece

Search for other papers by Labrini Papanastasiou in
Google Scholar
PubMed
Close
,
Stelios Tigas Department of Endocrinology, University of Ioannina, Ioannina, Greece

Search for other papers by Stelios Tigas in
Google Scholar
PubMed
Close
,
Konstantinos Toulis Department of Endocrinology, 424 Military Hospital, Thessaloniki, Greece

Search for other papers by Konstantinos Toulis in
Google Scholar
PubMed
Close
,
Kalliopi Pazaitou-Panayiotou Division of Endocrinology, Endocrine Oncology, Interbalkan Medical Center, Thessaloniki, Greece

Search for other papers by Kalliopi Pazaitou-Panayiotou in
Google Scholar
PubMed
Close
, and
Maria Alevizaki Endocrine Unit, Department of Medical Therapeutics, School of Medicine, Kapodistrian University of Athens, Athens, Greece

Search for other papers by Maria Alevizaki in
Google Scholar
PubMed
Close

]. RET (rearranged during transfection) proto-oncogene mutations play a key role in the pathogenesis of the disease. RET encodes a single-pass transmembrane protein receptor that belongs to receptor tyrosine kinase family. Activating germline mutations

Free access
Kirsten E. Stewart Department of Head and Neck Surgery, St John’s Hospital at Howden, Livingston, United Kingdom

Search for other papers by Kirsten E. Stewart in
Google Scholar
PubMed
Close
,
Mark W.J. Strachan Metabolic Unit, Western General Hospital, Edinburgh, United Kingdom

Search for other papers by Mark W.J. Strachan in
Google Scholar
PubMed
Close
,
Devraj Srinivasan Department of Oncology, Western General Hospital, Edinburgh, United Kingdom

Search for other papers by Devraj Srinivasan in
Google Scholar
PubMed
Close
,
Morna MacNeill Department of Pathology, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom

Search for other papers by Morna MacNeill in
Google Scholar
PubMed
Close
,
Lucy Wall Department of Oncology, Western General Hospital, Edinburgh, United Kingdom

Search for other papers by Lucy Wall in
Google Scholar
PubMed
Close
, and
Iain J. Nixon Department of Head and Neck Surgery, St John’s Hospital at Howden, Livingston, United Kingdom

Search for other papers by Iain J. Nixon in
Google Scholar
PubMed
Close

). What Does This Case Report Add? This case illustrates a patient with locally advanced DTC treated with tyrosine kinase inhibitor (TKI) therapy, which markedly reduced tumour volume and allowed subsequent successful surgical resection without

Free access
Satoshi Koyama Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine, Yonago, Japan

Search for other papers by Satoshi Koyama in
Google Scholar
PubMed
Close
,
Naritomo Miyake Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine, Yonago, Japan

Search for other papers by Naritomo Miyake in
Google Scholar
PubMed
Close
,
Kazunori Fujiwara Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine, Yonago, Japan

Search for other papers by Kazunori Fujiwara in
Google Scholar
PubMed
Close
,
Tsuyoshi Morisaki Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine, Yonago, Japan

Search for other papers by Tsuyoshi Morisaki in
Google Scholar
PubMed
Close
,
Takahiro Fukuhara Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine, Yonago, Japan

Search for other papers by Takahiro Fukuhara in
Google Scholar
PubMed
Close
,
Hiroya Kitano Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine, Yonago, Japan
Center for Head and Neck Surgery, Kusatsu General Hospital, Kusatsu, Japan

Search for other papers by Hiroya Kitano in
Google Scholar
PubMed
Close
, and
Hiromi Takeuchi Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine, Yonago, Japan

Search for other papers by Hiromi Takeuchi in
Google Scholar
PubMed
Close

strategies are required to improve the prognosis. Lenvatinib is an oral tyrosine kinase inhibitor targeting VEGFR1–3, FGFR1–4, RET, KIT, and PDGFRβ [ 6 - 8 ]. It was associated with a marked improvement in progression-free survival in patients with

Free access
Laura Ximena Kattah Martinez Pontificia Universidad Javeriana, Bogotá, Colombia

Search for other papers by Laura Ximena Kattah Martinez in
Google Scholar
PubMed
Close
,
Lisseth Fernanda Marín Carrillo Pontificia Universidad Javeriana, Bogotá, Colombia

Search for other papers by Lisseth Fernanda Marín Carrillo in
Google Scholar
PubMed
Close
, and
Leonardo Rojas Melo Pontificia Universidad Javeriana, Bogotá, Colombia

Search for other papers by Leonardo Rojas Melo in
Google Scholar
PubMed
Close

What Is Known About This Topic? Several side effects have been described with the use of tyrosine kinase inhibitors like sorafenib. Nonetheless, only 9 cases of pancreatitis related to sorafenib treatment have been described, all of them

Free access
Markus Eszlinger Departments of Oncology, Pathology and Laboratory Medicine, Biochemistry and Molecular Biology, and Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Heritage Medical Research Building, Calgary, Alberta, Canada
Institute of Pathology, University Hospital Halle (Saale), Halle (Saale), Germany

Search for other papers by Markus Eszlinger in
Google Scholar
PubMed
Close
,
Paul Stewardson Department of Medical Science and Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Paul Stewardson in
Google Scholar
PubMed
Close
,
John B McIntyre Precision Oncology Hub Laboratory, Alberta Health Services, Tom Baker Cancer Centre, Calgary, Alberta, Canada

Search for other papers by John B McIntyre in
Google Scholar
PubMed
Close
,
Adrian Box Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Adrian Box in
Google Scholar
PubMed
Close
,
Moosa Khalil Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Moosa Khalil in
Google Scholar
PubMed
Close
,
Martin Hyrcza Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Martin Hyrcza in
Google Scholar
PubMed
Close
,
Konstantin Koro Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Konstantin Koro in
Google Scholar
PubMed
Close
,
Dean Ruether Section of Medical Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Dean Ruether in
Google Scholar
PubMed
Close
,
Jiahui Wu Department of Medical Science and Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Jiahui Wu in
Google Scholar
PubMed
Close
, and
Ralf Paschke Departments of Medicine, Oncology, Pathology and Laboratory Medicine, Biochemistry and Molecular Biology, and Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Heritage Medical Research Building, Calgary, Alberta, Canada

Search for other papers by Ralf Paschke in
Google Scholar
PubMed
Close

Introduction The neurotrophic tyrosine kinase receptor (NTRK) inhibitors, larotrectinib and entrectinib, were approved by the United States Food & Drug Administration (FDA) for the treatment of NTRK fusion-positive solid tumors that are

Open access
Luisa Paschke Department of Endocrinology and Nephrology, Division of Endocrinology, University Clinic Leipzig, Leipzig, Germany
Department of Endocrinology and Nephrology, Division of Nephrology, University Clinic Leipzig, Leipzig, Germany

Search for other papers by Luisa Paschke in
Google Scholar
PubMed
Close
,
Thomas Lincke Department of Radiology, Division of Nuclear Medicine, University Clinic Leipzig, Leipzig, Germany

Search for other papers by Thomas Lincke in
Google Scholar
PubMed
Close
,
Katja Sibylle Mühlberg Department of Angiology, University Clinic Leipzig, Leipzig, Germany

Search for other papers by Katja Sibylle Mühlberg in
Google Scholar
PubMed
Close
,
Wolfram J. Jabs Department of Nephrology, Vivantes Clinics, Berlin, Germany

Search for other papers by Wolfram J. Jabs in
Google Scholar
PubMed
Close
,
Tom H. Lindner Department of Endocrinology and Nephrology, Division of Nephrology, University Clinic Leipzig, Leipzig, Germany

Search for other papers by Tom H. Lindner in
Google Scholar
PubMed
Close
, and
Ralf Paschke Division of Endocrinology, University of Calgary, Calgary, Alberta, Canada

Search for other papers by Ralf Paschke in
Google Scholar
PubMed
Close

treatment with lenvatinib and no concerning co-medications were reported. What Does This Case Report Add? We report two severe AEs of anti-VEGF tyrosine kinase inhibitor treatment which were not reported in the phase III trials. Our case

Free access
Francisco Sousa Santos Endocrinology Department, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal
Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Francisco Sousa Santos in
Google Scholar
PubMed
Close
,
Rita Joana Santos Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Rita Joana Santos in
Google Scholar
PubMed
Close
, and
Valeriano Leite Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Faculty of Medical Sciences of Lisbon, Lisbon, Portugal

Search for other papers by Valeriano Leite in
Google Scholar
PubMed
Close

a part in the pathogenesis of thyroid cancer and these represent potential treatment targets [ 6 ]. As such, several multitargeted tyrosine kinase inhibitors (TKIs) have been investigated for the treatment of RAI-refractory thyroid cancer with the

Free access
Sita Virakul Departments of Immunology, University Medical Center Rotterdam
Internal Medicine, Erasmus MC, University Medical Center Rotterdam

Search for other papers by Sita Virakul in
Google Scholar
PubMed
Close
,
Leendert van Steensel Departments of Immunology, University Medical Center Rotterdam

Search for other papers by Leendert van Steensel in
Google Scholar
PubMed
Close
,
Virgil A.S.H. Dalm Departments of Immunology, University Medical Center Rotterdam

Search for other papers by Virgil A.S.H. Dalm in
Google Scholar
PubMed
Close
,
Dion Paridaens Rotterdam Eye Hospital, Rotterdam, The Netherlands
Department of Ophthalmology, Geneva University Hospitals, Geneva, Switzerland

Search for other papers by Dion Paridaens in
Google Scholar
PubMed
Close
,
P. Martin van Hagen Departments of Immunology, University Medical Center Rotterdam
Internal Medicine, Erasmus MC, University Medical Center Rotterdam
Rotterdam Eye Hospital, Rotterdam, The Netherlands

Search for other papers by P. Martin van Hagen in
Google Scholar
PubMed
Close
, and
Willem A. Dik Departments of Immunology, University Medical Center Rotterdam

Search for other papers by Willem A. Dik in
Google Scholar
PubMed
Close

fibroblast functions In recent years numerous novel, targeted therapies have been introduced in clinical practice, like the biologicals and tyrosine kinase inhibitors (TKIs). Therapeutic strategies that target specific cytokines, growth factors or

Free access
Simone De Leo Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy

Search for other papers by Simone De Leo in
Google Scholar
PubMed
Close
,
Carla Colombo Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy

Search for other papers by Carla Colombo in
Google Scholar
PubMed
Close
,
Marta Di Stefano Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy

Search for other papers by Marta Di Stefano in
Google Scholar
PubMed
Close
,
Antonella Dubini Division of Laboratory Medicine, IRCCS Istituto Auxologico Italiano, Milan, Italy

Search for other papers by Antonella Dubini in
Google Scholar
PubMed
Close
,
Silvia Cozzi Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy

Search for other papers by Silvia Cozzi in
Google Scholar
PubMed
Close
,
Luca Persani Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy
Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy

Search for other papers by Luca Persani in
Google Scholar
PubMed
Close
, and
Laura Fugazzola Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy

Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
Close

biological characteristics of this tumor, which has a relatively low growth rate and is poorly symptomatic. Nevertheless, patients experience a relevant weight decrease when treatment with a tyrosine kinase inhibitor (TKI) is started, such as lenvatinib

Free access
Xian Qiu Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China

Search for other papers by Xian Qiu in
Google Scholar
PubMed
Close
,
Lin Cheng Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China

Search for other papers by Lin Cheng in
Google Scholar
PubMed
Close
,
Ri Sa Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
Department of Nuclear Medicine, The First Hospital of Jilin University, Changchun, China

Search for other papers by Ri Sa in
Google Scholar
PubMed
Close
,
Hao Fu Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
Department of Nuclear Medicine & Minnan PET Center, The First Affiliated Hospital of Xiamen University, Xiamen, China

Search for other papers by Hao Fu in
Google Scholar
PubMed
Close
,
Yuchen Jin Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA

Search for other papers by Yuchen Jin in
Google Scholar
PubMed
Close
, and
Libo Chen Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China

Search for other papers by Libo Chen in
Google Scholar
PubMed
Close

, including chemotherapy and external beam radiation therapy, remains limited in these challenging settings. In recent years, tyrosine kinase inhibitors (TKIs) such as sorafenib and lenvatinib have highlighted new therapeutic options for the treatment of

Open access